Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu of Company’s precision ...
Select mdx for Prostate Cancer is a proprietary urine-based mRNA test that offers a non-invasive method to assess a patient’s risk for clinically significant prostate cancer. Select mdx helps identify ...
MDxHealth has 4 validated testing products with one more in the clinical pipeline. All are focused specifically on urology. The company expects to do ~$65-$70M of sales in 2023, but the valuation is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results